PPIDT00382
Drug Information
| Name | Tildrakizumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB14004 |
| Type | biotech |
| Indication | Moderate-severe plaque psoriasis [L1858], [FDA label]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
100 MG
|
| Injection, solution | Parenteral; Subcutaneous |
200 mg
|
| Injection, solution | Subcutaneous |
100 mg
|
| Injection, solution | Subcutaneous |
100 mg/mL
|
| Injection, solution | Subcutaneous |
200 mg
|
| Injection, solution | Subcutaneous |
100 mg/1mL
|
| Solution | Subcutaneous |
100 mg / 1 mL
|
| Solution | Subcutaneous |
100 mg
|